Methods related to engineered erythoid cells comprising 4-1BBL
AssigneeRubius Therapeutics, Inc.
InventorsAvak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan Dowden, Tom Wickham, Sivan Elloul
Life of this patent
Estimating the term…
Abstract
The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
Claims28
A method of making a genetically engineered enucleated erythroid cell comprising a first exogenous polypeptide comprising a 4-1BB-binding fragment of 4-1BBL at the surface of the genetically engineered enucleated erythroid cell, comprising:
- (i) providing a nucleated erythroid cell, or a precursor thereof, comprising a first exogenous nucleic acid encoding the first exogenous polypeptide;
- and
- (ii) culturing the nucleated erythroid cell under conditions suitable for enucleation of the nucleated erythroid cell and for production of the first exogenous polypeptide.
Dependencies are inferred from the claim text.